Fortrea (FTRE) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
Meeting called to order at 8:00 A.M. Eastern Time on June 9, 2026, with board members and Deloitte & Touche present.
Rules of conduct and meeting format outlined, including proposal introductions and voting procedures.
Inspector of Election and secretary roles introduced and confirmed.
Corporate governance
Notice of meeting, proxy materials, and stockholder list confirmed and filed for inspection.
Quorum established with 86,193,770 shares represented, exceeding the majority required.
Board and executive committee updates
Three Class III director nominees presented: Peter M. Neupert, Anshul Thakral, and William J. Sharbaugh.
No additional nominations received; nominations declared closed.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Fortrea
- Demand, bookings, and technology integration are driving recovery and positioning for future growth.FTRE
Jefferies Global Healthcare Conference 20264 Jun 2026 - Adjusted EBITDA rose to $47M as net loss narrowed and guidance was reaffirmed.FTRE
Q1 20265 May 2026 - Annual meeting covers director elections, auditor ratification, and executive pay, with strong governance focus.FTRE
Proxy filing27 Apr 2026 - Votes will be held on director elections, auditor ratification, and executive pay approval.FTRE
Proxy filing27 Apr 2026 - Driving clinical trial modernization and margin expansion in a $40B global market.FTRE
44th Annual J.P. Morgan Healthcare Conference13 Apr 2026 - 2025 results met guidance; 2026 targets margin growth and stability despite goodwill impairment.FTRE
Q4 202526 Feb 2026 - Debt reduction, execution focus, and margin improvements drive confidence in 2024 guidance.FTRE
Fireside Chat3 Feb 2026 - Strong book-to-bill, commercial transformation, and debt reduction drive improved outlook.FTRE
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q2 2024 saw revenue and earnings decline, but sequential EBITDA and cash flow improved as debt fell.FTRE
Q2 20241 Feb 2026